NCT07599371招募中1 期
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
The First Affiliated Hospital of Zhengzhou University1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2024年10月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 29
- 试验地点
- 1
研究概览
简要总结
This study is a prospective, single-arm clinical trial aimed at evaluating the safety and efficacy of ivoximab combined with temozolomide in the treatment of relapsed/refractory glioma. The study plans to enroll 29 patients with relapsed/refractory glioma. After signing informed consent and meeting the inclusion/exclusion criteria through screening, patients will receive treatment with ivoximab combined with temozolomide. Efficacy evaluation will be conducted every two treatment cycles using the Response Assessment in Neuro-Oncology (RANO 2.0) criteria, and treatment will continue until disease progression or intolerance to the combined regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed/refractory glioma confirmed by histology and clinical imaging; ECOG performance status score of 0-1; Expected survival time ≥ 6 months; Adequate organ function, as demonstrated by meeting the following laboratory parameters; For female subjects of childbearing potential, a urine or serum pregnancy test must be performed within 3 days prior to the first dose of study drug (Cycle 1, Day 1), and the result must be negative. If the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test is required. A female of non-childbearing potential is defined as being postmenopausal for at least one year, or having undergone surgical sterilization or hysterectomy； If there is a risk of pregnancy, all subjects (both male and female) must use contraceptive measures with a failure rate of less than 1% per year throughout the entire treatment period until 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy).
排除标准
- •Diagnosis of another malignancy within 5 years prior to the first dose (excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ); Currently participating in interventional clinical research treatment, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose; Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); Receipt of systemic treatment with Chinese patent medicines with anti-tumor indications or immunomodulatory agents (including thymosin, interferon, interleukin, except for local use to control pleural effusion) within 2 weeks prior to the first dose; Active autoimmune disease requiring systemic treatment (e.g., with disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment; Receipt of systemic glucocorticoid therapy (excluding nasal spray, inhaled, or other topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose; Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted; Known history of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; Known allergy to any drug used in this study; Presence of factors affecting oral administration of temozolomide (e.g., inability to swallow, intestinal obstruction, etc.); Failure to fully recover from toxicity and/or complications caused by any previous intervention prior to the start of treatment (i.e., ≤ Grade 1 or return to baseline, excluding fatigue or alopecia); Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive); Untreated active hepatitis B (defined as HBsAg positive with detectable HBV-DNA copy number above the upper limit of normal of the testing center's laboratory); Subjects with active hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA level above the lower limit of detection); Receipt of a live vaccine within 30 days prior to the first dose (Cycle 1, Day 1); Note: Inactivated influenza vaccines administered by injection for seasonal influenza are permitted within 30 days prior to the first dose; however, intranasal live attenuated influenza vaccines are not permitted.
- •Pregnant or breastfeeding women; Presence of any severe or uncontrolled systemic disease; Evidence of medical history or disease, treatment, or abnormal laboratory values that may interfere with the study results or prevent the subject from fully participating in the study, or other conditions deemed by the investigator as unsuitable for enrollment, including potential risks that the investigator believes would make participation in this study inappropriate.
研究者
Chang Su
PhD/Attending Physician
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic CancerNCT07302841Tianjin Medical University Cancer Institute and Hospital28
尚未招募
不适用
Clinical Study on the Effects of VC-KON™ Vegan Collagen Supplement on Skin, Hair, Nails, and Joint Health in Healthy AdultsCTRI/2026/02/104931Konark Herbal & HealthCare Pvt. Ltd.30
尚未招募
不适用
A Study to Assess the Safety and Effectiveness of Bizfer XT Tablet (Iron, Zinc, Folic Acid, and Vitamin B12) in Improving Hemoglobin Levels in Patients with Iron Deficiency AnemiaCTRI/2025/07/090055J. B. chemicals & pharmaceuticals LTD.110
尚未招募
2 期
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCIntrahepatic CholangiocarcinomaNCT07432568Tianjin Medical University Cancer Institute and Hospital30
尚未招募
1 期
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic MalignanciesNCT07485504Tcelltech Inc.15